Human GluR6/GRIK2 Alexa Fluor® 750-conjugated Antibody Summary
Accession # Q13002
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
The Ionotropic Glutamate Receptors are a family of ligand-gated ion channels involved in regulating fast excitatory synaptic transmission in the central nervous system (CNS) (1, 2). The family consists of ~18 members which is divided into 3 groups based on the activating agonist: N-Methyl-D-Aspartate (NMDA), alpha -Amino-3-hydroxy-5-Methyl-4-isoxazole Propionic Acid (AMPA) and kainate (KA) (1, 2). KA receptors (KAR) are found in the pre- and postsynaptic membranes of the central nervous system, most prominently in the hippocampus, where they regulate synaptic transmission, neuronal excitability, and network activity (3). Glutamate receptor 6 (GluR6) (also Glutamate receptor ionotropic, kainate 2 or GluK2) along with GluR5, GluR7 and receptor subunits KA1 and KA2 belong to the KAR sub-group as these molecules are activated by kainic acid (1-3). Mature human GluR6 is a 3-transmembrane protein with a long (530 aa) N-terminal extracellular domain (ECD), a M2 domain involved in pore formation and a short C-terminal intracellular domain (4). The ECD of human GluR6 is highly conserved and shares 99% identity with both mouse and rat. Under physiological conditions, GluR6 forms either a homomeric or heteromeric receptor channel with GluR5 or KA1/2 to become functional (5, 6). Activation of KAR complexes result in Ca2+-dependent release of glutamatergic or GABAergic signals (7). The modulatory role of KARs make them attractive therapeutic candidates as glutamate excitotoxicity has been associated with multiple neurodegenerative and mental disorders. Misregulation of GluR6 has been suggested to be a factor in autism, Huntington disease and epilepsy (8). Additionally, GluR6 has been suggested to play a role in tumor suppression in Gastric cancer (9) while potentially displaying the opposite effect in urological cancers (10).
- Dingledine R et al. (1999) Pharmacol Rev. 51(1):7.
- Traynelis S.F et al. (2010) Pharmacol Rev. 62(3):405.
- Contractor A et al. (2011) Trends Neurosci. 34(3):154.
- Nanao MH et al. (2005) PNAS 102(5):1708.
- Kumar J et al. (2011) Neuron. 71(2):319.
- Fisher JL et al. (2011) J Neurosci. 31(47):17113.
- Mathew SS and Hablitz JJ (2008) Neuropharmacology. 55(1):106.
- Lerma J and Marques JM (2013) Neuron. 80(2):292.
- Wu CS et al. (2010) Int J Cancer. 126(11):2542.
- Inoue R. et al. (2017) Oncotarget. 8(17):28826.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human GluR6/GRIK2 Alexa Fluor® 750-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human GluR6/GRIK2 Alexa Fluor® 750-conjugated Antibody and earn rewards!
Have you used Human GluR6/GRIK2 Alexa Fluor® 750-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image